Aliskiren Hemifumarate
4 NDCs across 2 manufacturers|2 Generic,2 Brand
Aliskiren Hemifumarate is used to treat hypertension, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Mar 5, 2007, and the first generic was approved Mar 22, 2019. FDA's Orange Book lists 4 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $10 million on Aliskiren Hemifumarate across 31,000 claims for 7,150 beneficiaries.
Aliskiren Hemifumarate is available as 4 NDCs from 2 manufacturers (2 generic, 2 brand), with NADAC prices from $3.94 to $15.09 per EA — the most expensive product costs about 3.8× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
4
2G / 2B
Manufacturers
2
competing in market
Price Spread
$3.94 – $15.09
per EA
7d Activity
avg -0.1% WoW · of 4 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
LXO US Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Renin Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
2 manufacturers producing ALISKIREN HEMIFUMARATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
TEKTURNA 300 MG TABLET | $15.0945 per EA | — |
TEKTURNA 150 MG TABLET | $11.0782 per EA | — |
ALISKIREN 300 MG TABLET | $5.8584 per EA | +2.45% |
ALISKIREN 150 MG TABLET | $3.9375 per EA | -2.72% |
Frequently Asked Questions
What is Aliskiren Hemifumarate used to treat?
Aliskiren Hemifumarate is used to treat hypertension, per the National Library of Medicine's MED-RT classification.
When did Aliskiren Hemifumarate become available as a generic?
FDA approved the first generic Aliskiren Hemifumarate (ANDA) on Mar 22, 2019. The Orange Book currently lists 4 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Aliskiren Hemifumarate?
In 2024, Medicare Part D spent $10 million on Aliskiren Hemifumarate across 31,000 claims for 7,150 beneficiaries.
How many Aliskiren Hemifumarate products are on the market?
The Aliskiren Hemifumarate drug market contains 4 NDCs from 2 manufacturers — 2 generic and 2 brand products.
What is the price range for Aliskiren Hemifumarate?
NADAC reference prices for Aliskiren Hemifumarate range from $3.9375 to $15.0945 per EA — the most expensive product costs about 3.8× the cheapest.
Is generic Aliskiren Hemifumarate cheaper than brand?
The average generic NADAC for Aliskiren Hemifumarate is $4.8979 per EA, versus $13.0863 for brand-labeled products — brand versions average about 2.7× the generic price.
Which manufacturers make Aliskiren Hemifumarate?
2 manufacturers list Aliskiren Hemifumarate in NADAC. Ranked by number of NDCs, the largest are LXO US Inc. (2), Prasco Laboratories (2).
How has the price of Aliskiren Hemifumarate changed recently?
Over the past 7 days, 1 Aliskiren Hemifumarate NDC rose and 1 fell, with a market-wide average change of -0.1%.